Cited page

Citations are available only to our active members. Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

X X

Cited page

Display options
Reset

FDA Panels Back Black Box Warning on Antidepressants: Analysis of 24 Pediatric Trials Showed an Increased Suicidality Risk of 2%-3%

By: Mechcatie, Elizabeth | Clinical Psychiatry News, October 2004 | Article details

Look up
Saved work (0)

matching results for page

Why can't I print more than one page at a time?
While we understand printed pages are helpful to our users, this limitation is necessary to help protect our publishers' copyrighted material and prevent its unlawful distribution. We are sorry for any inconvenience.

FDA Panels Back Black Box Warning on Antidepressants: Analysis of 24 Pediatric Trials Showed an Increased Suicidality Risk of 2%-3%


Mechcatie, Elizabeth, Clinical Psychiatry News


BETHESDA, MD. -- A black box warning alerting prescribers to the risk of suicidal behavior and ideation with antidepressants in pediatric patients will likely be added to the labels of antidepressants, as recommended by the majority of the members of two Food and Drug Administration advisory panels.

At the end of a widely anticipated 2-day joint meeting, the FDA's psychopharmacologic drugs and pediatric advisory committees concluded that a reanalysis of the suicidality data from 23 pediatric trials of antidepressants, and a recently published trial of fluoxetine, indicated that those drugs were associated with an increased risk of suicidality--a term defined by the FDA as suicidal behavior and ideation.

An FDA analysis of 24 clinical trials determined that the increased risk over placebo was about 2%-3%, which, despite the limitations of the studies, was described as a "reasonably consistent signal for risk" by Dr. Thomas Laughren, leader of the FDA's psychiatric drug products group.

The relative risks of nine newer antidepressants in the trials--citalopram (Celexa), fluvoxamine (Luvox), paroxetine (Paxil), fluoxetine (Prozac), sertraline (Zoloft), venlafaxine (Effexor XR), mirtazapine (Remeron), nefazodone (Serzone), and bupropion (Wellbutrin)--varied, and most of the risks came from but were not limited to trials of major depressive disorder (MDD).

The panels agreed that it was better not to specify a chemical class of antidepressants, but antidepressants as a class. They also opted not to specify one disorder, since there was an increased risk detected in non-MDD trials of some of the drugs.

Panel members then voted 15-8 in favor of adding a black box warning to convey this information to prescribers. Dr. Robert …

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Select text to:

Select text to:

  • Highlight
  • Cite a passage
  • Look up a word
Learn more Close
Loading One moment ...
Highlight
Select color
Change color
Delete highlight
Cite this passage
Cite this highlight
View citation

Are you sure you want to delete this highlight?